WO1991012021A3 - Therapeutic agents, and intermediates for the synthesis thereof - Google Patents

Therapeutic agents, and intermediates for the synthesis thereof Download PDF

Info

Publication number
WO1991012021A3
WO1991012021A3 PCT/GB1991/000215 GB9100215W WO9112021A3 WO 1991012021 A3 WO1991012021 A3 WO 1991012021A3 GB 9100215 W GB9100215 W GB 9100215W WO 9112021 A3 WO9112021 A3 WO 9112021A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutically active
cells
therapeutic agents
organ
group
Prior art date
Application number
PCT/GB1991/000215
Other languages
French (fr)
Other versions
WO1991012021A2 (en
Inventor
Jonathan Miles-Brown
Original Assignee
Oxford Virology Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909003257A external-priority patent/GB9003257D0/en
Priority claimed from GB909006500A external-priority patent/GB9006500D0/en
Application filed by Oxford Virology Plc filed Critical Oxford Virology Plc
Publication of WO1991012021A2 publication Critical patent/WO1991012021A2/en
Publication of WO1991012021A3 publication Critical patent/WO1991012021A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Abstract

Therapeutic agents are provided which are adapted to deliver a therapeutically active substance to a selected cell, group of cells or organ and to intermediates useful in synthesising said agents. The therapeutic agents comprise a therapeutically active substance covalently linked to a polypeptide of low molecular weight, which polypeptide comprises an amino acid sequence which is recognised by a recognition site of a receptor of a selected cell, group of cells or organ. The therapeutic agent may be therapeutically active itself and/or is convertible at or within the selected cell, group of cells or organ to a form which is therapeutically active. Examples of target cells are CD4 lymphocytes, and the amino acid sequence comprises a sequence which is recognised by the CD4 receptor.
PCT/GB1991/000215 1990-02-13 1991-02-13 Therapeutic agents, and intermediates for the synthesis thereof WO1991012021A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9003257.4 1990-02-13
GB909003257A GB9003257D0 (en) 1990-02-13 1990-02-13 Therapeutic agents and intermediates for the synthesis thereof
GB909006500A GB9006500D0 (en) 1990-03-23 1990-03-23 Therapeutic agents,and intermediates for the synthesis thereof
GB9006500.4 1990-03-23

Publications (2)

Publication Number Publication Date
WO1991012021A2 WO1991012021A2 (en) 1991-08-22
WO1991012021A3 true WO1991012021A3 (en) 1991-12-12

Family

ID=26296657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/000215 WO1991012021A2 (en) 1990-02-13 1991-02-13 Therapeutic agents, and intermediates for the synthesis thereof

Country Status (2)

Country Link
AU (1) AU7217891A (en)
WO (1) WO1991012021A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233036T3 (en) * 1998-04-27 2005-06-01 Opperbas Holding B.V. PHARMACEUTICAL COMPOSITION THAT INCLUDES FACTOR VIII AND NEUTRAL LIPOSOMES.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279688A2 (en) * 1987-02-20 1988-08-24 Genentech, Inc. Methods and compositions for the use of HIV env polypeptides and antibodies thereto
EP0314317A1 (en) * 1987-10-02 1989-05-03 Genentech, Inc. Adheson variants, nucleic acid encoding them and compositions comprising them
WO1989010754A1 (en) * 1988-05-04 1989-11-16 Igen, Inc. Therapeutic methods using catalytic antibodies
WO1990012868A1 (en) * 1989-04-25 1990-11-01 Tanox Biosystems, Inc. Antibodies specific for cd4-binding domain of hiv

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279688A2 (en) * 1987-02-20 1988-08-24 Genentech, Inc. Methods and compositions for the use of HIV env polypeptides and antibodies thereto
EP0314317A1 (en) * 1987-10-02 1989-05-03 Genentech, Inc. Adheson variants, nucleic acid encoding them and compositions comprising them
WO1989010754A1 (en) * 1988-05-04 1989-11-16 Igen, Inc. Therapeutic methods using catalytic antibodies
WO1990012868A1 (en) * 1989-04-25 1990-11-01 Tanox Biosystems, Inc. Antibodies specific for cd4-binding domain of hiv

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biochemical Pharmacology, vol. 40, no. 12, 1990, Pergamon Press Plc, (GB), G. Molema et al.: "Targeting of antiviral drugs to T4-lymphocytes", pages 2603-2610, see the abstract *
File Server, STN, File CA, & Chemical Abstracts, vol. 106, C.B. Pert et al.: "Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity", see abstract no. 48291e, & Proc. Natl. Acad. Sci. USA, 83(23), 9254-8 *
File Server, STN, File CA, & Chemical Abstracts, vol. 113, K.M. Callahan et al.: "Genetic variability in HIV-1 GP120 affects interactions with HLA molecules and T cell receptor", see abstract no. 113335h, & J. Immunol., 144(9), 3341-6 *
STN, File Server, Karlsruhe, File CA, & Chemical Abstracts, vol. 109, R.F. Siliciano et al.: "Analysis of host-virus interactions in aids with anti-GP120 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion", see abstract no. 188532w, & Cell (Cambridge, Mass.), 54(4), 561-75 *

Also Published As

Publication number Publication date
WO1991012021A2 (en) 1991-08-22
AU7217891A (en) 1991-09-03

Similar Documents

Publication Publication Date Title
US9409945B2 (en) Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
EP0862455B1 (en) Interferon-polymer conjugates and process for preparing the same
US9238697B2 (en) Polymeric materials and methods
EP1188768A3 (en) LHRH antagonist peptides
EP1859811A1 (en) Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy
US4261886A (en) Peptides having thymopoietin-like activity
EP0632722A1 (en) A dna transporter system and method of use
AU2001278797A1 (en) Expression vector using for animal cell
CA2127463A1 (en) Biodegradable polymers for cell transplantation
IL112372A (en) Non-viral vector for the delivery of genetic information to cells
JPH03504013A (en) Peptide with T cell helper activity
CA2420350A1 (en) Membrane penetrating peptides and uses thereof
NZ233642A (en) Linked hemoglobin subunits, preparation by genetic engineering and linker assay
FI104252B1 (en) Method for solid phase chemical synthesis of therapeutically useful peptides
US5686423A (en) Di-and tri-peptide mimetic compounds for Parkinson's disease
AU677374B2 (en) Monoclonal anti-LFA-1 antibodies for the preparation of a medicament intended to prevent the rejection of organ transplants
CA2110055A1 (en) T cell receptor peptides as therapeutics for immune-related disease
CA2163225A1 (en) Lhrh antagonists
WO1991012021A3 (en) Therapeutic agents, and intermediates for the synthesis thereof
DE3151738C2 (en)
CA1157466A (en) Peptides having thymopoietin-like activity
WO2003086273A8 (en) Histone conjugates and uses thereof
CA1250400A (en) Peptides having influence on memory processes, processes for producing them and pharmaceutical compositions containing them
CA2139571A1 (en) Interferon receptor binding peptides
Manfredini et al. Peptide T-araC conjugates: solid-phase synthesis and biological activity of N4-(acylpeptidyl)-araC

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA